- Home
- DDI vs ITOS Comparison
DDI vs ITOS Comparison
Compare DDI & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DDI
- ITOS
- Stock Information
- Founded
- DDI 2008
- ITOS 2011
- Country
- DDI South Korea
- ITOS United States
- Employees
- DDI N/A
- ITOS N/A
- Industry
- DDI EDP Services
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DDI Technology
- ITOS Health Care
- Exchange
- DDI Nasdaq
- ITOS Nasdaq
- Market Cap
- DDI 472.2M
- ITOS 450.9M
- IPO Year
- DDI 2021
- ITOS 2020
- Fundamental
- Price
- DDI $9.30
- ITOS N/A
- Analyst Decision
- DDI Strong Buy
- ITOS Hold
- Analyst Count
- DDI 5
- ITOS 6
- Target Price
- DDI $19.60
- ITOS $10.40
- AVG Volume (30 Days)
- DDI 48.9K
- ITOS 1.6M
- Earning Date
- DDI 11-10-2025
- ITOS 08-06-2025
- Dividend Yield
- DDI N/A
- ITOS N/A
- EPS Growth
- DDI N/A
- ITOS N/A
- EPS
- DDI 2.15
- ITOS N/A
- Revenue
- DDI $333,256,000.00
- ITOS N/A
- Revenue This Year
- DDI $14.45
- ITOS N/A
- Revenue Next Year
- DDI $5.69
- ITOS N/A
- P/E Ratio
- DDI $4.38
- ITOS N/A
- Revenue Growth
- DDI 0.24
- ITOS 177.89
- 52 Week Low
- DDI $8.09
- ITOS $4.80
- 52 Week High
- DDI $18.21
- ITOS $17.63
- Technical
- Relative Strength Index (RSI)
- DDI 41.26
- ITOS 1.63
- Support Level
- DDI $9.28
- ITOS $10.10
- Resistance Level
- DDI $9.74
- ITOS $10.17
- Average True Range (ATR)
- DDI 0.23
- ITOS 0.02
- MACD
- DDI -0.02
- ITOS -0.80
- Stochastic Oscillator
- DDI 6.67
- ITOS 0.00
About DDI DoubleDown Interactive Co. Ltd. American Depository Shares
DoubleDown Interactive Co Ltd is a developer and publisher of digital games on mobile and web-based platforms. The company is the creator of multi-format interactive entertainment experiences for casual players. The company's operating segments include the social casino games segment and the iGaming segment. The company generates the majority of its revenue from social casino games. Geographically, the company generates the majority of its revenue from the United States.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.